文献速递垂体与肾上腺疾病

瑞拉单抗联合纳武利尤单抗治疗后肾上腺皮质功能不全的风险高于预期

The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究为回顾性分析,纳入2015至2023年Mass General Brigham医疗系统接受瑞拉单抗联合纳武利尤单抗治疗的患者,按年龄、性别和种族匹配至接受纳武利尤单抗单药治疗者。结果显示联合治疗组肾上腺皮质功能不全发生率为8%(10例),单药组低于1%(1例)(P = .00056),联合治疗组中位给药次数为7次(4-10)高于未发生者的3次(2-6)(P = .03)。

要点

  • 瑞拉单抗联合纳武利尤单抗组肾上腺皮质功能不全发生率为8%(10例),纳武利尤单抗单药组低于1%(1例)(P = .00056)。
  • 联合治疗组中发生肾上腺皮质功能不全者中位给药次数为7次(4-10),未发生者为3次(2-6)(P = .03)。
  • 最常见的首发症状为乏力、食欲减退、恶心和呕吐。

核心结论

  • 瑞拉单抗联合纳武利尤单抗治疗相比纳武利尤单抗单药治疗,发生肾上腺皮质功能不全的风险显著更高,可能继发于垂体炎。
  • 本研究是首个比较瑞拉单抗联合纳武利尤单抗与纳武利尤单抗单药治疗患者垂体炎的队列分析。

研究设计与样本

  • 回顾性分析Mass General Brigham医疗系统2015至2023年接受瑞拉单抗联合纳武利尤单抗治疗的患者,按年龄、性别和种族匹配至接受纳武利尤单抗单药治疗者。

主要发现

  • 瑞拉单抗联合纳武利尤单抗组10例(8%)诊断为肾上腺皮质功能不全,纳武利尤单抗单药组1例(低于1%)诊断为肾上腺皮质功能不全(P = .00056)。
  • 联合治疗组中,发生与未发生肾上腺皮质功能不全的患者中位年龄和性别构成可比。
  • 联合治疗组中发生肾上腺皮质功能不全者中位给药次数为7次(4-10),未发生者为3次(2-6)(P = .03)。
  • 最常见的首发症状为乏力、食欲减退、恶心和呕吐。
  • 无患者被诊断出其他垂体前叶激素缺乏或精氨酸加压素缺乏,但并非所有患者均接受了这些诊断的评估。

局限性

  • 本研究为回顾性分析。
  • 并非所有患者均接受了其他垂体前叶激素缺乏或精氨酸加压素缺乏的诊断评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenal insufficiency from hypophysitis is a complication of immune checkpoint inhibitor (ICI) therapy. However, the risk associated with relatlimab, a lymphocyte-activation gene 3 inhibitor, is unknown. Relatlimab was approved in 2022 in combination with nivolumab for the treatment of unresectable or metastatic melanoma. OBJECTIVE: To determine the prevalence, identify risk factors, and characterize the clinical presentation of central adrenal insufficiency in patients receiving relatlimab-nivolumab compared to nivolumab alone. METHODS: Retrospective analysis of Mass General Brigham healthcare system patients who received relatlimab-nivolumab from 2015 to 2023 matched by age, sex, and race to individuals receiving monotherapy with nivolumab, an ICI with a risk of hypophysitis of <1%. RESULTS: Adrenal insufficiency was diagnosed in 10 patients (8%) after relatlimab-nivolumab administration and in 1 patient (<1%) after nivolumab monotherapy (P = .00056). Within the relatlimab-nivolumab group, median age and sex were comparable in patients who developed adrenal insufficiency compared to those who did not. The median number of doses received by subjects who developed adrenal insufficiency was 7 (4-10) compared to 3 (2-6) in those who did not (P = .03). The most common presenting symptoms were fatigue, anorexia, nausea, and vomiting. No patients were diagnosed with additional anterior pituitary hormone deficiencies or arginine vasopressin deficiency, though not all patients were evaluated for these diagnoses. CONCLUSION: This study is the first cohort analysis of hypophysitis in patients treated with relatlimab-nivolumab compared to nivolumab monotherapy. Combination treatment with relatlimab-nivolumab confers a significantly higher risk of developing adrenal insufficiency, likely secondary to hypophysitis, compared to nivolumab alone.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chamorro-Pareja N, Faje AT, Miller KK, et al. The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected. J Clin Endocrinol Metab. 2025. PMID: 40001294. doi:10.1210/clinem/dgaf122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。